Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ
|ClinicalTrials.gov Identifier: NCT00505830|
Recruitment Status : Unknown
Verified July 2007 by Groupe Francais d'Epidemiologie Psychiatrique.
Recruitment status was: Recruiting
First Posted : July 25, 2007
Last Update Posted : July 25, 2007
|First Submitted Date||July 23, 2007|
|First Posted Date||July 25, 2007|
|Last Update Posted Date||July 25, 2007|
|Study Start Date||July 2007|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures||Not Provided|
|Original Primary Outcome Measures||Not Provided|
|Change History||No Changes Posted|
|Current Secondary Outcome Measures||Not Provided|
|Original Secondary Outcome Measures||Not Provided|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title||Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ|
|Official Title||Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome : Autism Spectrum Quotient (AQ) Empathy Quotient (EQ) and Systemizing Quotient (SQ)|
Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50.
The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire.
Secondary objectives are to:
Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS.
Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents.
Define the threshold of positivity for the 3 questionnaires.
4 groups of participants will be screened with the questionnaires: Group 1: 50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
Group 2: 50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
Group 3: 50 adolescents with psychiatric disorders. Group 4: Sample of 50 healthy adolescents selected randomly from 200. The questionnaires are given to the parents of adolescents during the first meeting. Parents are invited to send them back to the clinical investigation centre of Lyon (France).
Multicentre study: 8 clinical centres and 18 paediatricians
|Study Design||Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Not Provided|
|Study Population||Not Provided|
Autism Spectrum Quotient (AQ)
Secondary outcome measure:
Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status||Unknown status|
|Original Estimated Enrollment||Same as current|
|Estimated Study Completion Date||July 2009|
|Primary Completion Date||Not Provided|
Group 1 (AS/HFA) and 2 (AS/classic autism) :
Group 3 (adolescents with psychiatric disorders):
Group 4 (adolescent without psychiatric syndrome):
For all groups :
|Ages||12 Years to 18 Years (Child, Adult)|
|Accepts Healthy Volunteers||Yes|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||France|
|Removed Location Countries|
|Other Study ID Numbers||Autisme AQ|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Not Provided|
|Study Sponsor||Groupe Francais d'Epidemiologie Psychiatrique|
|Collaborators||Joint Clinical Research Center|
|PRS Account||Groupe Francais d'Epidemiologie Psychiatrique|
|Verification Date||July 2007|